{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:43:39Z","timestamp":1792449819520,"version":"4.5.0"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1055\/a-2820-6490","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:30:28Z","timestamp":1792449028000},"page":"1177-1183","source":"Crossref","is-referenced-by-count":0,"title":["Membran\u00f6se Glomerulonephritis"],"prefix":"10.1055","volume":"151","author":[{"given":"Maya","family":"Machalitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular Pathogenesis of Membranous Nephropathy","volume":"15","author":"P Ronco","year":"2020","journal-title":"Annu Rev Pathol"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJMe0903343","article-title":"Human idiopathic membranous nephropathy \u2013 a mystery solved?","volume":"361","author":"RJ Glassock","year":"2009","journal-title":"N Engl J Med"},{"issue":"03","key":"ref3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD Atlas of Renal Pathology: Membranous Nephropathy","volume":"66","author":"AB Fogo","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1681\/ASN.2011030304","article-title":"Basic and translational concepts of immune-mediated glomerular diseases","volume":"23","author":"WG Couser","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"LH Beck Jr","year":"2009","journal-title":"N Engl J Med"},{"issue":"03","key":"ref6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of Human Anti-PLA 2 R1 Antibodies in Minipigs: A Pilot Study","volume":"34","author":"L Reinhard","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"ref7","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"JM Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"06","key":"ref8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"E Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"09","key":"ref9","doi-asserted-by":"publisher","first-page":"e0221293","DOI":"10.1371\/journal.pone.0221293","article-title":"Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy","volume":"14","author":"M Mahmud","year":"2019","journal-title":"PLoS One"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.kint.2020.07.039","article-title":"NELL1 is a target antigen in malignancy-associated membranous nephropathy","volume":"99","author":"TN Caza","year":"2021","journal-title":"Kidney Int"},{"issue":"24","key":"ref11","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"NM Tomas","year":"2014","journal-title":"N Engl J Med"},{"issue":"09","key":"ref12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","article-title":"Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome","volume":"32","author":"T Wiech","year":"2019","journal-title":"Mod Pathol"},{"issue":"04","key":"ref13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"BH Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.kint.2022.09.011","article-title":"False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy","volume":"103","author":"E Hoxha","year":"2023","journal-title":"Kidney Int"},{"issue":"02","key":"ref15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"M Fresquet","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"LH Beck Jr","year":"2014","journal-title":"J Clin Invest"},{"issue":"01","key":"ref17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000364782","article-title":"Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies","volume":"40","author":"N Leeaphorn","year":"2014","journal-title":"Am J Nephrol"},{"issue":"04","key":"ref18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/gcc.22440","article-title":"THSD7A expression in human cancer","volume":"56","author":"PR Stahl","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"ref19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification","volume":"98","author":"S Sethi","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"01","key":"ref20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0002-9343(79)90486-8","article-title":"Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients","volume":"66","author":"LH Noel","year":"1979","journal-title":"Am J Med"},{"issue":"02","key":"ref21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"A Schieppati","year":"1993","journal-title":"N Engl J Med"},{"issue":"09","key":"ref22","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"Glomerulonephritis Registry. The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"MA Hladunewich","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/0886022X.2022.2068442","article-title":"Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels","volume":"44","author":"Y Sun","year":"2022","journal-title":"Ren Fail"},{"issue":"03","key":"ref24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"DC Cattran","year":"1997","journal-title":"Kidney Int"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/ndt\/gfv228","article-title":"Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy","volume":"30","author":"E Hoxha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"05","key":"ref26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"D Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"01","key":"ref27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"S Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"S 03","key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf116.0233","article-title":"#0181 Efficacy and safety of apixaban in patients with nephrotic syndrome: a prospective longitudinal cohort study","volume":"40","author":"I Mykhaloiko","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"05","key":"ref29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"D Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"01","key":"ref30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"FC Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group","volume":"47","author":"DC Cattran","year":"1995","journal-title":"Kidney Int"},{"issue":"09","key":"ref32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"M Praga","year":"2007","journal-title":"Kidney Int"},{"issue":"9868","key":"ref33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"A Howman","year":"2013","journal-title":"Lancet"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2820-6490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:30:33Z","timestamp":1792449033000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2820-6490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2026,10,19]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2820-6490","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}